Cost-effectiveness of a nitric oxide-generating medical device in managing hard-to-heal diabetic foot ulcers.

IF 1.5 4区医学 Q3 DERMATOLOGY

Journal of wound care Pub Date : 2025-07-02 DOI:10.12968/jowc.2024.0417

Julian F Guest, Michael E Edmonds

{"title":"Cost-effectiveness of a nitric oxide-generating medical device in managing hard-to-heal diabetic foot ulcers.","authors":"Julian F Guest, Michael E Edmonds","doi":"10.12968/jowc.2024.0417","DOIUrl":null,"url":null,"abstract":"Objective: To explore the potential cost-effectiveness of using a nitric oxide-generating medical device (EDX110, ConvaNiox, Convatec Ltd., UK) in the management of hard-to-heal diabetic foot ulcers (DFUs) among patients with type 1 or 2 diabetes, from the perspective of the UK's health services.Method: Markov modelling simulated the management of infected and non-infected hard-to-heal (chronic) DFUs with EDX110 or standard care in the community and secondary care over a 24-week period. The model was constructed using data from a previous randomised controlled trial and was used to estimate the potential cost-effectiveness of EDX110 in terms of the incremental cost per quality-adjusted life year (QALY) gained at 2021/22 prices.Results: There was a 63% improvement in healing by 24 weeks in the EDX110 group compared with standard care (49% versus 30%, respectively). This led to a 6% improvement in health-related quality of life and a 20% reduction in the total cost of DFU management. At a purchase price of £40 per EDX110 dressing, it was found to afford a cost-effective treatment in >80% of a cohort. However, the location where the dressing is administered (i.e., the community or secondary care) can potentially influence EDX110's cost-effectiveness.Conclusion: Within the limitations of the study, EDX110 could potentially afford the UK's health services a cost-effective treatment for DFUs; however, this is dependent on the location of the healthcare professionals administering the dressing.","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 7","pages":"476-486"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of wound care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/jowc.2024.0417","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore the potential cost-effectiveness of using a nitric oxide-generating medical device (EDX110, ConvaNiox, Convatec Ltd., UK) in the management of hard-to-heal diabetic foot ulcers (DFUs) among patients with type 1 or 2 diabetes, from the perspective of the UK's health services.

Method: Markov modelling simulated the management of infected and non-infected hard-to-heal (chronic) DFUs with EDX110 or standard care in the community and secondary care over a 24-week period. The model was constructed using data from a previous randomised controlled trial and was used to estimate the potential cost-effectiveness of EDX110 in terms of the incremental cost per quality-adjusted life year (QALY) gained at 2021/22 prices.

Results: There was a 63% improvement in healing by 24 weeks in the EDX110 group compared with standard care (49% versus 30%, respectively). This led to a 6% improvement in health-related quality of life and a 20% reduction in the total cost of DFU management. At a purchase price of £40 per EDX110 dressing, it was found to afford a cost-effective treatment in >80% of a cohort. However, the location where the dressing is administered (i.e., the community or secondary care) can potentially influence EDX110's cost-effectiveness.

Conclusion: Within the limitations of the study, EDX110 could potentially afford the UK's health services a cost-effective treatment for DFUs; however, this is dependent on the location of the healthcare professionals administering the dressing.

查看原文本刊更多论文

一种产生一氧化氮的医疗装置在治疗难以治愈的糖尿病足溃疡中的成本效益。

目的：从英国卫生服务的角度，探讨使用一氧化氮生成医疗装置（EDX110, ConvaNiox, Convatec Ltd.， UK）治疗1型或2型糖尿病患者难以愈合的糖尿病足溃疡（DFUs）的潜在成本效益。方法：马尔可夫模型模拟了24周内EDX110或社区标准护理和二级护理对感染和非感染难以治愈（慢性）DFUs的管理。该模型使用先前随机对照试验的数据构建，并用于根据2021/22价格获得的每个质量调整生命年（QALY）的增量成本来估计EDX110的潜在成本效益。结果：与标准治疗相比，EDX110组24周的愈合率提高了63%（分别为49%和30%）。这导致与健康相关的生活质量提高了6%，DFU管理总成本降低了20%。每个EDX110敷料的购买价格为40英镑，研究发现，在80%的队列中，EDX110敷料提供了具有成本效益的治疗。然而，敷料实施的地点（即社区或二级保健）可能会影响EDX110的成本效益。结论：在本研究的限制范围内，EDX110可能为英国的医疗服务提供一种具有成本效益的治疗dfu的方法；然而，这取决于医疗保健专业人员管理敷料的位置。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of wound care DERMATOLOGY-

CiteScore

2.90

自引率

10.50%

发文量

215

期刊介绍： Journal of Wound Care (JWC) is the definitive wound-care journal and the leading source of up-to-date research and clinical information on everything related to tissue viability. The journal was first launched in 1992 and aimed at catering to the needs of the multidisciplinary team. Published monthly, the journal’s international audience includes nurses, doctors and researchers specialising in wound management and tissue viability, as well as generalists wishing to enhance their practice. In addition to cutting edge and state-of-the-art research and practice articles, JWC also covers topics related to wound-care management, education and novel therapies, as well as JWC cases supplements, a supplement dedicated solely to case reports and case series in wound care. All articles are rigorously peer-reviewed by a panel of international experts, comprised of clinicians, nurses and researchers. Specifically, JWC publishes: High quality evidence on all aspects of wound care, including leg ulcers, pressure ulcers, the diabetic foot, burns, surgical wounds, wound infection and more The latest developments and innovations in wound care through both preclinical and preliminary clinical trials of potential new treatments worldwide In-depth prospective studies of new treatment applications, as well as high-level research evidence on existing treatments Clinical case studies providing information on how to deal with complex wounds Comprehensive literature reviews on current concepts and practice, including cost-effectiveness Updates on the activities of wound care societies around the world.